Health
Biocon Gets European Commission Nod for Pebrilzo, Its Breast Cancer Biosimilar
Biocon has received marketing authorisation from the European Commission for Pebrilzo, its pertuzumab biosimilar for HER2-positive breast cancer. It is the first biosimilar to be cleared under the European Medicines Agency's new tailored clinical approach.